DOCSLIB.ORG

Cyclooxygenase-Derived Proangiogenic Metabolites of Epoxyeicosatrienoic Acids

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cyclooxygenase-Derived Proangiogenic Metabolites of Epoxyeicosatrienoic Acids Cyclooxygenase-derived proangiogenic metabolites of epoxyeicosatrienoic acids Amy A. Randa,b, Bogdan Barnycha,b, Christophe Morisseaua,b, Tomas Cajkac, Kin Sing Stephen Leea,b, Dipak Panigrahyd,e, and Bruce D. Hammocka,b,1 aDepartment of Entomology and Nematology, University of California, Davis, CA 95616; bUC Davis Comprehensive Cancer Center, University of California, Davis, CA 95616; cWest Coast Metabolomics Center, UC Davis Genome Center, University of California, Davis, CA 95616; dCenter for Vascular Biology Research, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115; and eDepartment of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115 Contributed by Bruce D. Hammock, March 2, 2017 (sent for review October 12, 2016; reviewed by James F. Callahan and A. Daniel Jones) Arachidonic acid (ARA) is metabolized by cyclooxygenase (COX) which suppress the formation of prostaglandins (16). Compared and cytochrome P450 to produce proangiogenic metabolites. with sEH inhibitors, COX inhibitors (i.e., the COX-2 selective Specifically, epoxyeicosatrienoic acids (EETs) produced from the inhibitor celecoxib) suppress angiogenesis and tumor growth, P450 pathway are angiogenic, inducing cancer tumor growth. A whereas sEH inhibitors alone tend to stimulate these same re- – previous study showed that inhibiting soluble epoxide hydrolase sponses in animals on a high omega-6 fat diet (15). It was (sEH) increased EET concentration and mildly promoted tumor therefore surprising that administration of a dual sEH and COX growth. However, inhibiting both sEH and COX led to a dramatic inhibitor led to an antiangiogenic and anticancer response more decrease in tumor growth, suggesting that the contribution of pronounced than administration of these inhibitors alone (15). Similarly, when a COX (celecoxib) and sEH inhibitor (trans-4- EETs to angiogenesis and subsequent tumor growth may be [4-(3-adamantan-1-ylureido)cyclohexyloxy]benzoic acid; t-AUCB) attributed to downstream metabolites formed by COX. This study were administered simultaneously to mice, tumor growth was explores the fate of EETs with COX, the angiogenic activity of much more inhibited than administration of the same two inhibitors the primary metabolites formed, and their subsequent hydrolysis alone, as shown in Fig. 1B (15). These results indicate that coin- by sEH and microsomal EH. Three EET regioisomers were found to cubation with a COX and sEH inhibitor produces a synergistic be substrates for COX, based on oxygen consumption and product effect, better at inhibiting primary tumor growth and metastasis formation. EET substrate preference for both COX-1 and COX-2 through the suppression of cancer angiogenesis. This suggests that were estimated as 8,9-EET > 5,6-EET > 11,12-EET, whereas 14,15- EETs, whose levels are controlled by sEH, are metabolized by EET was inactive. The structure of two major products formed COX to form angiogenic, protumorigenic products that enhance from 8,9-EET in this COX pathway were confirmed by chemical the procancer response of EETs. Inhibiting COX decreases their synthesis: ct-8,9-epoxy-11-hydroxy-eicosatrienoic acid (ct-8,9-E- formation and activity, as observed in a previous study (16). 11-HET) and ct-8,9-epoxy-15-hydroxy-eicosatrienoic acid (ct-8,9- The link between the COX and sEH pathways that stimulates E-15-HET). ct-8,9-E-11-HET and ct-8,9-E-15-HET are further metab- angiogenesis and tumor progression may be explained by a rel- olized by sEH, with ct-8,9-E-11-HET being hydrolyzed much more atively unexplored pathway associated with EET metabolism. slowly. Using an s.c. Matrigel assay, we showed that ct-8,9-E-11- Although EETs are primarily metabolized by sEH, a few studies HET is proangiogenic, whereas ct-8,9-E-15-HET is not active. This have observed that the 5,6-EET and 8,9-EET are substrates for study identifies a functional link between EETs and COX and COX-1 (17, 18) and COX-2 (19). The COX metabolites of EETs ct have largely undefined biological activity, yet Homma et al. de- identifies -8,9-E-11-HET as an angiogenic lipid, suggesting a phys- ct iological role for COX metabolites of EETs. termined that the -8,9-epoxy-11-hydroxy-eicosatrienoic acid (ct-8,9-E-11-HET) metabolite is a renal vasoconstrictor and potent mitogen, approximately three orders of magnitude more omega-6 fatty acids | epoxyeicosatrienoic acids | metabolism | potent than its parent, 8,9-EET (20). This provides evidence that cyclooxygenase | angiogenesis EETs undergo metabolism by COX, forming metabolites that have greater activity than their parent compounds. If these COX rachidonic acid (ARA) is an omega-6 fatty acid that is metabolites are also angiogenic, this activity may be mitigated Ametabolized by three major classes of enzymes, cyclo- with COX inhibitors. oxygenases (COXs), lipoxygenases, and cytochrome P450s (CYPs), to produce an array of biologically active metabolites (1–3). The Significance CYP pathway transforms ARA into four epoxyeicosatrienoic acids (EETs) in addition to hydroxylated metabolites (1). EETs have This study furthers our understanding of epoxyeicosatrienoic several biological actions, and are considered antihypertensive, acid metabolism by cyclooxygenase (COX) enzymes as a phys- antiinflammatory, neuroprotective, cardioprotective, and analgesic iologically relevant metabolic pathway, producing signaling (4). EETs also play a role in angiogenesis (5–10), the formation of molecules that are angiogenic. It explains, in part, why inhib- new blood vessels from preexisting vessels that is important for many iting the soluble epoxide hydrolase (sEH) in some systems is physiological and pathological processes, including cancer (11). angiogenic whereas combining sEH inhibition with COX in- EETs can enhance tumor growth and metastasis through their hibition is dramatically antiangiogenic, which in turn may angiogenic activity (12); however, this activity is transient due to suppress tumor growth. their metabolic instability. EETs are further metabolized by epoxide hydrolases (EHs), primarily soluble epoxide hydrolase Author contributions: A.A.R., B.B., C.M., D.P., and B.D.H. designed research; A.A.R., B.B., (sEH), to their corresponding diols (4, 13), which are generally C.M., T.C., and D.P. performed research; B.B., T.C., and K.S.S.L. contributed new reagents/ not biologically active (14) (Fig. 1A). Inhibition of sEH prolongs analytic tools; A.A.R., C.M., and B.D.H. analyzed data; and A.A.R., B.B., C.M., T.C., K.S.S.L., EET biological activity, potentiating their angiogenic activity, D.P., and B.D.H. wrote the paper. leading to increased tumor growth and metastasis in some sys- Reviewers: J.F.C., GlaxoSmithKline; and A.D.J., Michigan State University. tems (12, 15) (Fig. 1B). The authors declare no conflict of interest. ARA can also be metabolized by COX to form proangiogenic 1To whom correspondence should be addressed. Email: [email protected]. and proinflammatory prostaglandins (16). Angiogenesis stimulated This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. from exposure to ARA can be mediated using COX inhibitors, 1073/pnas.1616893114/-/DCSupplemental. 4370–4375 | PNAS | April 25, 2017 | vol. 114 | no. 17 www.pnas.org/cgi/doi/10.1073/pnas.1616893114 Downloaded by guest on September 27, 2021 t P > K ABArachidonic literature values (independent test, 0.05) (21). Likewise, M Acid (ARA) *** values for 8,9-EET with COX-1 and COX-2 are not significantly CYP 8000 different from the ARA KMs, indicating that both substrates have ) V 3 similar affinities for both enzymes. All values obtained for m 6000 also showed no significant difference. 11,12-EET gave rates that 5,6 EET 5,6-epoxy-PGH2 * COX were so low that the kinetic constants could not be calculated 8,9 EET 4000 based on the response curves, and 14,15-EET showed no apparent ct-8,9-E-11-HET reaction with COX-1 or COX-2 (SI Appendix, Figs. S3 and S4). 11,12 EET 2000 With respect to the enzymatic mechanism, epoxides placed at Tumor Volume (mm the 11,12 and 14,15 positions may alter the substrate orientation 14,15 EET ct-8,9-E-15-HET within the enzyme, limiting apparent reactivity. COX first cata- Epoxyeicosatrienoic 0 Acids (EETs) lyzes oxygenation by abstracting the substrate’s 13-proS-hydro- trol sEH Con gen, generating a radical with maximal electron density at C-11 Celecoxib Dihydroxy sEHi t-AUCB and C-15, where oxygen then adds to form a peroxyl radical Eicosatrienoic (22). Epoxides placed in either of these locations may limit the Acids (DHETs) t-AUCB + Celecoxib initial abstraction rate and addition of oxygen, compared with Fig. 1. ARA is metabolized by CYP to form metabolites that enhance an- epoxides placed further from the initial catalytic C-13 (i.e., 5,6- giogenesis and tumor growth. (A) EETs are metabolized by sEH to less active and 8,9-EET). 14,15-EET was least active compared with the dihydroxyeicosatrienoic acids and by COX to hydroxy-EETs (ct-8,9-E-11-HET other regioisomers, possibly due to the epoxide proximity to the and ct-8,9-E-15-HET) and prostaglandin analogs (5,6-epoxy-PGH2), regulators ω-end of the fatty acid. Because the ω-end resides within a of mitogenesis, vasoactivity, and angiogenesis. sEH inhibition preserves and channel at the top of the COX active site, substrates with sub- increases EET levels, thought responsible for angiogenesis and increased stituents closer to the ω-end may further limit COX activity tumor growth, yet COX inhibition blocks this activity. (B) Tumor volume is through added steric hindrance within this channel. For example, altered by the selective COX-2 inhibitor celecoxib and an sEH inhibitor (sEHi adding bulky substitutions within this channel has been shown to t-AUCB).
Load more

Recommended publications
  • Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid
    Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 231 _____________________________ _____________________________ Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21 BY JOHAN BYLUND ACTA UNIVERSITATIS UPSALIENSIS UPPSALA 2000 Dissertation for the Degree of Doctor of Philosophy (Faculty of Pharmacy) in Pharmaceutical Pharmacology presented at Uppsala University in 2000 ABSTRACT Bylund, J. 2000. Cytochrome P450 Enzymes in Oxygenation of Prostaglandin Endoperoxides and Arachidonic Acid: Cloning, Expression and Catalytic Properties of CYP4F8 and CYP4F21. Acta Universitatis Upsaliensis. Comprehensive Summaries of Uppsala Dissertations from Faculty of Pharmacy 231 50 pp. Uppsala. ISBN 91-554-4784-8. Cytochrome P450 (P450 or CYP) is an enzyme system involved in the oxygenation of a wide range of endogenous compounds as well as foreign chemicals and drugs. This thesis describes investigations of P450-catalyzed oxygenation of prostaglandins, linoleic and arachidonic acids. The formation of bisallylic hydroxy metabolites of linoleic and arachidonic acids was studied with human recombinant P450s and with human liver microsomes. Several P450 enzymes catalyzed the formation of bisallylic hydroxy metabolites. Inhibition studies and stereochemical analysis of metabolites suggest that the enzyme CYP1A2 may contribute to the biosynthesis of bisallylic hydroxy fatty acid metabolites in adult human liver microsomes. 19R-Hydroxy-PGE and 20-hydroxy-PGE are major components of human and ovine semen, respectively. They are formed in the seminal vesicles, but the mechanism of their biosynthesis is unknown. Reverse transcription-polymerase chain reaction using degenerate primers for mammalian CYP4 family genes, revealed expression of two novel P450 genes in human and ovine seminal vesicles.
    [Show full text]
  • Inhibition of Cytochrome P450 2C8-Mediated Drug Metabolism by the Flavonoid Diosmetin
    Drug Metab. Pharmacokinet. 26 (6): 559­568 (2011). Copyright © 2011 by the Japanese Society for the Study of Xenobiotics (JSSX) Regular Article Inhibition of Cytochrome P450 2C8-mediated Drug Metabolism by the Flavonoid Diosmetin Luigi QUINTIERI1,PietroPALATINI1,StefanoMORO2 and Maura FLOREANI1,* 1Department of Pharmacology and Anaesthesiology, University of Padova, Italy 2Molecular Modeling Section (MMS), Department of Pharmaceutical Sciences, University of Padova, Italy Full text of this paper is available at http://www.jstage.jst.go.jp/browse/dmpk Summary: The aim of this study was to assess the effects of diosmetin and hesperetin, two flavonoids present in various medicinal products, on CYP2C8 activity of human liver microsomes using paclitaxel oxidation to 6¡-hydroxy-paclitaxel as a probe reaction. Diosmetin and hesperetin inhibited 6¡-hydroxy- paclitaxel production in a concentration-dependent manner, diosmetin being about 16-fold more potent than hesperetin (mean IC50 values 4.25 « 0.02 and 68.5 « 3.3 µM for diosmetin and hesperetin, respectively). Due to the low inhibitory potency of hesperetin, we characterized the mechanism of diosmetin-induced inhibition only. This flavonoid proved to be a reversible, dead-end, full inhibitor of CYP2C8, its mean inhibition constant (Ki)being3.13« 0.11 µM. Kinetic analysis showed that diosmetin caused mixed-type inhibition, since it significantly decreased the Vmax (maximum velocity) and increased the Km value (substrate concentration yielding 50% of Vmax) of the reaction. The results of kinetic analyses were consistent with those of molecular docking simulation, which showed that the putative binding site of diosmetin coincided with the CYP2C8 substrate binding site. The demonstration that diosmetin inhibits CYP2C8 at concentrations similar to those observed after in vivo administration (in the low micromolar range) is of potential clinical relevance, since it may cause pharmacokinetic interactions with co- administered drugs metabolized by this CYP.
    [Show full text]
  • Synonymous Single Nucleotide Polymorphisms in Human Cytochrome
    DMD Fast Forward. Published on February 9, 2009 as doi:10.1124/dmd.108.026047 DMD #26047 TITLE PAGE: A BIOINFORMATICS APPROACH FOR THE PHENOTYPE PREDICTION OF NON- SYNONYMOUS SINGLE NUCLEOTIDE POLYMORPHISMS IN HUMAN CYTOCHROME P450S LIN-LIN WANG, YONG LI, SHU-FENG ZHOU Department of Nutrition and Food Hygiene, School of Public Health, Peking University, Beijing 100191, P. R. China (LL Wang & Y Li) Discipline of Chinese Medicine, School of Health Sciences, RMIT University, Bundoora, Victoria 3083, Australia (LL Wang & SF Zhou). 1 Copyright 2009 by the American Society for Pharmacology and Experimental Therapeutics. DMD #26047 RUNNING TITLE PAGE: a) Running title: Prediction of phenotype of human CYPs. b) Author for correspondence: A/Prof. Shu-Feng Zhou, MD, PhD Discipline of Chinese Medicine, School of Health Sciences, RMIT University, WHO Collaborating Center for Traditional Medicine, Bundoora, Victoria 3083, Australia. Tel: + 61 3 9925 7794; fax: +61 3 9925 7178. Email: [email protected] c) Number of text pages: 21 Number of tables: 10 Number of figures: 2 Number of references: 40 Number of words in Abstract: 249 Number of words in Introduction: 749 Number of words in Discussion: 1459 d) Non-standard abbreviations: CYP, cytochrome P450; nsSNP, non-synonymous single nucleotide polymorphism. 2 DMD #26047 ABSTRACT Non-synonymous single nucleotide polymorphisms (nsSNPs) in coding regions that can lead to amino acid changes may cause alteration of protein function and account for susceptivity to disease. Identification of deleterious nsSNPs from tolerant nsSNPs is important for characterizing the genetic basis of human disease, assessing individual susceptibility to disease, understanding the pathogenesis of disease, identifying molecular targets for drug treatment and conducting individualized pharmacotherapy.
    [Show full text]
  • Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice
    pharmaceutics Review Mechanisms of CYP450 Inhibition: Understanding Drug-Drug Interactions Due to Mechanism-Based Inhibition in Clinical Practice Malavika Deodhar 1, Sweilem B Al Rihani 1 , Meghan J. Arwood 1, Lucy Darakjian 1, Pamela Dow 1 , Jacques Turgeon 1,2 and Veronique Michaud 1,2,* 1 Tabula Rasa HealthCare Precision Pharmacotherapy Research and Development Institute, Orlando, FL 32827, USA; [email protected] (M.D.); [email protected] (S.B.A.R.); [email protected] (M.J.A.); [email protected] (L.D.); [email protected] (P.D.); [email protected] (J.T.) 2 Faculty of Pharmacy, Université de Montréal, Montreal, QC H3C 3J7, Canada * Correspondence: [email protected]; Tel.: +1-856-938-8697 Received: 5 August 2020; Accepted: 31 August 2020; Published: 4 September 2020 Abstract: In an ageing society, polypharmacy has become a major public health and economic issue. Overuse of medications, especially in patients with chronic diseases, carries major health risks. One common consequence of polypharmacy is the increased emergence of adverse drug events, mainly from drug–drug interactions. The majority of currently available drugs are metabolized by CYP450 enzymes. Interactions due to shared CYP450-mediated metabolic pathways for two or more drugs are frequent, especially through reversible or irreversible CYP450 inhibition. The magnitude of these interactions depends on several factors, including varying affinity and concentration of substrates, time delay between the administration of the drugs, and mechanisms of CYP450 inhibition. Various types of CYP450 inhibition (competitive, non-competitive, mechanism-based) have been observed clinically, and interactions of these types require a distinct clinical management strategy. This review focuses on mechanism-based inhibition, which occurs when a substrate forms a reactive intermediate, creating a stable enzyme–intermediate complex that irreversibly reduces enzyme activity.
    [Show full text]
  • CYP2J2 Expression in Adult Ventricular Myocytes Protects Against Reactive Oxygen Species Toxicity S
    Supplemental material to this article can be found at: http://dmd.aspetjournals.org/content/suppl/2018/01/17/dmd.117.078840.DC1 1521-009X/46/4/380–386$35.00 https://doi.org/10.1124/dmd.117.078840 DRUG METABOLISM AND DISPOSITION Drug Metab Dispos 46:380–386, April 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics CYP2J2 Expression in Adult Ventricular Myocytes Protects Against Reactive Oxygen Species Toxicity s Eric A. Evangelista, Rozenn N. Lemaitre, Nona Sotoodehnia, Sina A. Gharib, and Rheem A. Totah Department of Medicinal Chemistry (E.A.E., R.A.T.), Cardiovascular Health Research Unit, Department of Medicine (R.N.L., N.S.), Division of Cardiology (N.S.), and Computational Medicinal Core, Center for Lung Biology, Division of Pulmonary and Critical Care Medicine, Department of Medicine (S.A.G.), University of Washington, Seattle, Washington Received October 4, 2017; accepted January 11, 2018 ABSTRACT Cytochrome P450 2J2 isoform (CYP2J2) is a drug-metabolizing silencing on cells when levels of reactive oxygen species (ROS) enzyme that is highly expressed in adult ventricular myocytes. It is are elevated. Findings indicate that CYP2J2 expression increases in Downloaded from responsible for the bioactivation of arachidonic acid (AA) into response to external ROS or when internal ROS levels are elevated. epoxyeicosatrienoic acids (EETs). EETs are biologically active In addition, cell survival decreases with ROS exposure when CYP2J2 signaling compounds that protect against disease progression, is chemically inhibited or when CYP2J2 expression is reduced using particularly in cardiovascular diseases. As a drug-metabolizing small interfering RNA. These effects are mitigated with external enzyme, CYP2J2 is susceptible to drug interactions that could lead addition of EETs to the cells.
    [Show full text]
  • Simulation of Physicochemical and Pharmacokinetic Properties of Vitamin D3 and Its Natural Derivatives
    pharmaceuticals Article Simulation of Physicochemical and Pharmacokinetic Properties of Vitamin D3 and Its Natural Derivatives Subrata Deb * , Anthony Allen Reeves and Suki Lafortune Department of Pharmaceutical Sciences, College of Pharmacy, Larkin University, Miami, FL 33169, USA; [email protected] (A.A.R.); [email protected] (S.L.) * Correspondence: [email protected] or [email protected]; Tel.: +1-224-310-7870 or +1-305-760-7479 Received: 9 June 2020; Accepted: 20 July 2020; Published: 23 July 2020 Abstract: Vitamin D3 is an endogenous fat-soluble secosteroid, either biosynthesized in human skin or absorbed from diet and health supplements. Multiple hydroxylation reactions in several tissues including liver and small intestine produce different forms of vitamin D3. Low serum vitamin D levels is a global problem which may origin from differential absorption following supplementation. The objective of the present study was to estimate the physicochemical properties, metabolism, transport and pharmacokinetic behavior of vitamin D3 derivatives following oral ingestion. GastroPlus software, which is an in silico mechanistically-constructed simulation tool, was used to simulate the physicochemical and pharmacokinetic behavior for twelve vitamin D3 derivatives. The Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) Predictor and PKPlus modules were employed to derive the relevant parameters from the structural features of the compounds. The majority of the vitamin D3 derivatives are lipophilic (log P values > 5) with poor water solubility which are reflected in the poor predicted bioavailability. The fraction absorbed values for the vitamin D3 derivatives were low except for calcitroic acid, 1,23S,25-trihydroxy-24-oxo-vitamin D3, and (23S,25R)-1,25-dihydroxyvitamin D3-26,23-lactone each being greater than 90% fraction absorbed.
    [Show full text]
  • Regular Article Cytochrome P450 Is Responsible for Nitric Oxide Generation from NO-Aspirin and Other Organic Nitrates
    Drug Metab. Pharmacokinet. 22 (1): 15–19 (2007). Regular Article Cytochrome P450 is Responsible for Nitric Oxide Generation from NO-Aspirin and Other Organic Nitrates Yukiko MINAMIYAMA1,2,*,ShigekazuTAKEMURA2, Susumu IMAOKA3, Yoshihiko FUNAE4,andShigeruOKADA1 1Department of Anti-aging Food Sciences, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan, Departments of 2Hepato-Biliary-Pancreatic Surgery and 4Chemical Biology, Graduate School of Medicine, Osaka City University, Osaka, Japan, 3School of Science and Technology Kwansei Gakuin University, Sanda, Japan Full text of this paper is available at http://www.jstage.jst.go.jp/browse/dmpk Summary: Nitric oxide (NO) biotransformation from NO-aspirin (NCX-4016) is not clearly understood. We have previously reported that cytochrome P450 (P450) plays important role in NO generation from other organic nitrates such as nitroglycerin (NTG) and isosorbide dinitrate (ISDN). The present study was designed to elucidate the role of human cytochrome P450 isoforms in NO formation from NCX-4016, using lymphoblast microsomes transfected with cDNA of human P450 or yeast-expressed, puriˆed P450 isoforms. CYP1A2 and CYP2J2, among other isoforms, were strongly related to NO production from NCX-4016. In fact, these isoforms were detected in human coronary endothelial cells. These results suggest that NADPH-cytochrome P450 reductase and the P450 system participate in NO formation from NCX-4016, as well as other organic nitrates. Key words: human cytochrome
    [Show full text]
  • Time-Dependent Inhibition of CYP2C8 and CYP2C19 by Hedera Helix Extracts, a Traditional Respiratory Herbal Medicine
    molecules Article Time-dependent Inhibition of CYP2C8 and CYP2C19 by Hedera helix Extracts, A Traditional Respiratory Herbal Medicine Shaheed Ur Rehman 1, In Sook Kim 2, Min Sun Choi 2, Seung Hyun Kim 3, Yonghui Zhang 4 and Hye Hyun Yoo 2,* 1 Department of Pharmacy, COMSATS Institute of Information Technology, Abbottabad 22060, Pakistan; [email protected] 2 Institute of Pharmaceutical Science and Technology and College of Pharmacy, Hanyang University, Ansan, Gyeonggi-do 15588, Korea; [email protected] (I.S.K.); [email protected] (M.S.C.) 3 College of Pharmacy, Yonsei Institute of Pharmaceutical Science, Yonsei University, Incheon 21983, Korea; [email protected] 4 School of Pharmacy, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China; [email protected] * Correspondence: [email protected]; Tel.: +82-31-400-5804; Fax: +82-31-400-5958 Received: 1 June 2017; Accepted: 20 July 2017; Published: 24 July 2017 Abstract: The extract of Hedera helix L. (Araliaceae), a well-known folk medicine, has been popularly used to treat respiratory problems, worldwide. It is very likely that this herbal extract is taken in combination with conventional drugs. The present study aimed to evaluate the effects of H. helix extract on cytochrome P450 (CYP) enzyme-mediated metabolism to predict the potential for herb–drug interactions. A cocktail probe assay was used to measure the inhibitory effect of CYP. H. helix extracts were incubated with pooled human liver microsomes or CYP isozymes with CYP-specific substrates, and the formation of specific metabolites was investigated to measure the inhibitory effects.
    [Show full text]
  • Detection of Human CYP2C8, CYP2C9 and CYP2J2 in Cardiovascular
    DMD Fast Forward. Published on January 12, 2007 as DOI: 10.1124/dmd.106.012823 DMD FastThis Forward.article has not Published been copyedited on and January formatted. 12, The 2007final version as doi:10.1124/dmd.106.012823 may differ from this version. DMD #12823 Detection of Human CYP2C8, CYP2C9 and CYP2J2 in Cardiovascular Tissues Tracy C. DeLozier, Grace E. Kissling, Sherry J. Coulter, Diana Dai, Julie F. Foley, J. Alyce Bradbury, Elizabeth Murphy, Charles Steenbergen, Darryl C. Zeldin Downloaded from and Joyce A. Goldstein dmd.aspetjournals.org Human Metabolism Section, Laboratory of Pharmacology and Chemistry, (T.C.D., S.J.C., at ASPET Journals on September 27, 2021 D.D. and J.A.G.); Laboratory of Respiratory Biology, (J.A.B., and D.C.Z.); Laboratory of Experimental Pathology, (J.F.F.); Biostatistics Branch (G.E.K.) and Laboratory of Signal Transduction (E.M.); NIEHS, Research Triangle Park, North Carolina 27709 and Department of Pathology, Duke University Medical Center, Durham, N.C (C.S.). Copyright 2007 by the American Society for Pharmacology and Experimental Therapeutics. DMD Fast Forward. Published on January 12, 2007 as DOI: 10.1124/dmd.106.012823 This article has not been copyedited and formatted. The final version may differ from this version. DMD #12823 Running Title: Detection of CYP2Cs in Cardiovascular Tissues To whom correspondence should be addressed: Dr. Joyce A. Goldstein National Institute of Environmental Health Sciences 111 T.W. Alexander Drive Research Triangle Park, NC 27709 Tel: 919-541-4495 Downloaded from Fax: 919-541-3647 Email: [email protected] dmd.aspetjournals.org Text pages: 28 Number of tables: 3 Number of Figures: 7 at ASPET Journals on September 27, 2021 Number of References: 40 Abstract: 246 Introduction: 687 Discussion: 1047 Abbreviations: CYP: Cytochrome P450.
    [Show full text]
  • Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese Population
    Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population The Harvard community has made this article openly available. Please share how this access benefits you. Your story matters Citation Halling, Jónrit, Maria S. Petersen, Per Damkier, Flemming Nielsen, Philippe Grandjean, Pál Weihe, Stefan Lundgren, Mia Sandberg Lundblad, and Kim Brøsen. 2005. “Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese Population.” European Journal of Clinical Pharmacology 61 (7) (July 16): 491–497. doi:10.1007/s00228-005-0938-1. Published Version doi:10.1007/s00228-005-0938-1 Citable link http://nrs.harvard.edu/urn-3:HUL.InstRepos:34786606 Terms of Use This article was downloaded from Harvard University’s DASH repository, and is made available under the terms and conditions applicable to Other Posted Material, as set forth at http:// nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of- use#LAA POLYMORPHISM OF CYP2D6, CYP2C19, CYP2C9 AND CYP2C8 IN THE FAROESE POPULATION Jónrit Halling1, Maria S. Petersen2, Per Damkier3, Flemming Nielsen1,2 , Philippe Grandjean2, Pál Weihe4, Stefan Lundgren5, Mia Sandberg Lundblad5 and Kim Brøsen1 1 Institute of Public Health, Clinical Pharmacology, University of Southern Denmark, Winslovparken 19, 5000 Odense C, Denmark. 2 Institute of Public Health, Enviromental Medicine, University of Southern Denmark, Winslovparken 17, 5000 Odense C, Denmark. 3Department KKA, Clinical Pharmacology, Odense University Hospital, Odense, Denmark 4 The Faroese Hospital System, Department of Occupational
    [Show full text]
  • Early Pregnancy Maternal Progesterone Administration Alters Pituitary and Testis Function and Steroid Profile in Male Fetuses
    www.nature.com/scientificreports OPEN Early pregnancy maternal progesterone administration alters pituitary and testis function and steroid profle in male fetuses Katarzyna J. Siemienowicz1,2*, Yili Wang1, Magda Marečková1, Junko Nio‑Kobayashi1,3, Paul A. Fowler4, Mick T. Rae2 & W. Colin Duncan1 Maternal exposure to increased steroid hormones, including estrogens, androgens or glucocorticoids during pregnancy results in chronic conditions in ofspring that manifest in adulthood. Little is known about efects of progesterone administration in early pregnancy on fetal development. We hypothesised that maternal early pregnancy progesterone supplementation would increase fetal progesterone, afect progesterone target tissues in the developing fetal reproductive system and be metabolised to other bioactive steroids in the fetus. We investigated the efects of progesterone treatment during early pregnancy on maternal and fetal plasma progesterone concentrations, transcript abundance in the fetal pituitary and testes and circulating steroids, at day 75 gestation, using a clinically realistic ovine model. Endogenous progesterone concentrations were lower in male than female fetuses. Maternal progesterone administration increased male, but not female, fetal progesterone concentrations, also increasing circulating 11‑dehydrocorticosterone in male fetuses. Maternal progesterone administration altered fetal pituitary and testicular function in ovine male fetuses. This suggests that there may be fetal sex specifc efects of the use of progesterone in early pregnancy, and highlights that progesterone supplementation should be used only when there is clear evidence of efcacy and for as limited time as necessary. Fetal exposure to sex steroids has critical roles in sexual diferentiation and the programming of health and dis- ease in later life1. Exposure to endocrine disrupting compounds is linked to disease development in ofspring2.
    [Show full text]
  • Recent Advances in P450 Research
    The Pharmacogenomics Journal (2001) 1, 178–186 2001 Nature Publishing Group All rights reserved 1470-269X/01 $15.00 www.nature.com/tpj REVIEW Recent advances in P450 research JL Raucy1,2 ABSTRACT SW Allen1,2 P450 enzymes comprise a superfamily of heme-containing proteins that cata- lyze oxidative metabolism of structurally diverse chemicals. Over the past few 1La Jolla Institute for Molecular Medicine, San years, there has been significant progress in P450 research on many fronts Diego, CA 92121, USA; 2Puracyp Inc, San and the information gained is currently being applied to both drug develop- Diego, CA 92121, USA ment and clinical practice. Recently, a major accomplishment occurred when the structure of a mammalian P450 was determined by crystallography. Correspondence: Results from these studies will have a major impact on understanding struc- JL Raucy,La Jolla Institute for Molecular Medicine,4570 Executive Dr,Suite 208, ture-activity relationships of P450 enzymes and promote prediction of drug San Diego,CA 92121,USA interactions. In addition, new technologies have facilitated the identification Tel: +1 858 587 8788 ext 116 of several new P450 alleles. This information will profoundly affect our under- Fax: +1 858 587 6742 E-mail: jraucyȰljimm.org standing of the causes attributed to interindividual variations in drug responses and link these differences to efficacy or toxicity of many thera- peutic agents. Finally, the recent accomplishments towards constructing P450 null animals have afforded determination of the role of these enzymes in toxicity. Moreover, advances have been made towards the construction of humanized transgenic animals and plants. Overall, the outcome of recent developments in the P450 arena will be safer and more efficient drug ther- apies.
    [Show full text]